BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruneau S, Néel M, Roumenina LT, Frimat M, Laurent L, Frémeaux-Bacchi V, Fakhouri F. Loss of DGKε induces endothelial cell activation and death independently of complement activation. Blood 2015;125:1038-46. [PMID: 25498910 DOI: 10.1182/blood-2014-06-579953] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, Azaiez H, Black-Ziegelbein EA, Meyer NC, Kolbe DL, Li Y, Frees K, Schnieders MJ, Thomas C, Nester C, Smith RJ. High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies. J Am Soc Nephrol 2016;27:1245-53. [PMID: 26283675 DOI: 10.1681/ASN.2015040385] [Cited by in Crossref: 60] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
2 Stokman MF, Renkema KY, Giles RH, Schaefer F, Knoers NV, van Eerde AM. The expanding phenotypic spectra of kidney diseases: insights from genetic studies. Nat Rev Nephrol 2016;12:472-83. [PMID: 27374918 DOI: 10.1038/nrneph.2016.87] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
3 Vijayan KV. DGKE disruption ditches complement and drives p38 signaling. Blood 2015;125:898-9. [PMID: 25655457 DOI: 10.1182/blood-2014-12-617589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020;130:2152-63. [PMID: 32310222 DOI: 10.1172/JCI136094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 36.0] [Reference Citation Analysis]
5 Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J, Evans J, Finlay E, Freundlich M, Gale DP, Inward C, Mraz M, Jones C, Wong W, Marks SD, Connolly J, Corner BM, Smith-Jackson K, Walsh PR, Marchbank KJ, Harris CL, Wilson V, Wong EKS, Malina M, Johnson S, Sheerin NS, Kavanagh D. Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int 2020;97:1260-74. [PMID: 32386968 DOI: 10.1016/j.kint.2020.01.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
6 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
7 Conway EM. HUS and the case for complement. Blood. 2015;126:2085-2090. [PMID: 26396094 DOI: 10.1182/blood-2015-03-569277] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
8 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
9 Nestor JG, Groopman EE, Gharavi AG. Towards precision nephrology: the opportunities and challenges of genomic medicine. J Nephrol 2018;31:47-60. [PMID: 29043570 DOI: 10.1007/s40620-017-0448-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
10 Günay N, Pınarbaşı AS, Doğan ME, Yel S, Balaban AG, Dursun İ, Eken A, Akgün H, Dündar M, Poyrazoğlu MH. A rare cause of membranoproliferative patterns of injury in siblings with steroid-resistant nephrotic syndrome: Answers. Pediatr Nephrol 2021. [PMID: 34185135 DOI: 10.1007/s00467-021-05154-0] [Reference Citation Analysis]
11 Hwang M, Han MH, Park HH, Choi H, Lee KY, Lee YJ, Kim JM, Cheong JH, Ryu JI, Min KW, Oh YH, Ko Y, Koh SH. LGR5 and Downstream Intracellular Signaling Proteins Play Critical Roles in the Cell Proliferation of Neuroblastoma, Meningioma and Pituitary Adenoma. Exp Neurobiol 2019;28:628-41. [PMID: 31698554 DOI: 10.5607/en.2019.28.5.628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol 2019;15:87-108. [PMID: 30607032 DOI: 10.1038/s41581-018-0098-z] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 34.7] [Reference Citation Analysis]
13 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Epand RM, So V, Jennings W, Khadka B, Gupta RS, Lemaire M. Diacylglycerol Kinase-ε: Properties and Biological Roles. Front Cell Dev Biol 2016;4:112. [PMID: 27803897 DOI: 10.3389/fcell.2016.00112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
15 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
16 Meinel C, Spartà G, Dahse HM, Hörhold F, König R, Westermann M, Coldewey SM, Cseresnyés Z, Figge MT, Hammerschmidt S, Skerka C, Zipfel PF. Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells. J Infect Dis 2018;217:358-70. [PMID: 28968817 DOI: 10.1093/infdis/jix305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
17 Vieira-martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-bacchi V. Defining the genetics of thrombotic microangiopathies. Transfusion and Apheresis Science 2016;54:212-9. [DOI: 10.1016/j.transci.2016.04.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
18 Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Frémeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Prohászka Z, Killen P, Gipson P, Sampson MG, Lemaire M, Schaefer F. The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. J Am Soc Nephrol 2017;28:3066-75. [PMID: 28526779 DOI: 10.1681/ASN.2017010031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 5.6] [Reference Citation Analysis]
19 Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016;221:715-8. [DOI: 10.1016/j.imbio.2015.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Miyata T, Uchida Y, Ohta T, Urayama K, Yoshida Y, Fujimura Y. Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations. Thromb Haemost 2015;114:862-3. [PMID: 26018111 DOI: 10.1160/TH15-01-0007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
21 Chen YY, Han SS, Cao Y, Yu XJ, Zhu L, Luo JC, Song WC, Yu F, Mao YH, Zhao MH. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. Clin Immunol 2021;229:108794. [PMID: 34245915 DOI: 10.1016/j.clim.2021.108794] [Reference Citation Analysis]
22 Brodsky RA. Complement in hemolytic anemia. Hematology 2015;2015:385-91. [DOI: 10.1182/asheducation-2015.1.385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li J, Song Y, Zhang Y, Li H, Tian M, Li D, Zhang S, Cao G, Liu C. A novel compound heterozygous mutation in DGKE in a Chinese patient causes atypical hemolytic uremic syndrome. Hematology 2020;25:101-7. [PMID: 32091318 DOI: 10.1080/16078454.2020.1731969] [Reference Citation Analysis]
24 Chauvet S, Roumenina LT, Bruneau S, Marinozzi MC, Rybkine T, Schramm EC, Java A, Atkinson JP, Aldigier JC, Bridoux F, Touchard G, Fremeaux-Bacchi V. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol 2016;27:1665-77. [PMID: 26471127 DOI: 10.1681/ASN.2015040348] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
25 Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015;125:3637-46. [PMID: 25862562 DOI: 10.1182/blood-2015-02-629683] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
26 Rawish E, Sauter M, Sauter R, Nording H, Langer HF. Complement, inflammation and thrombosis. Br J Pharmacol 2021;178:2892-904. [PMID: 33817781 DOI: 10.1111/bph.15476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
28 Brodsky RA. Complement in hemolytic anemia. Blood 2015;126:2459-65. [DOI: 10.1182/blood-2015-06-640995] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
29 Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement System Part II: Role in Immunity. Front Immunol 2015;6:257. [PMID: 26074922 DOI: 10.3389/fimmu.2015.00257] [Cited by in Crossref: 353] [Cited by in F6Publishing: 385] [Article Influence: 50.4] [Reference Citation Analysis]
30 Zhou D, Tan Y, Liu X, Tang L, Wang H, Shen J, Wang W, Zhuang L, Tao J, Su J, Gong T, Liu X, Liang P, Yu F, Zhao M. Patient-specific iPSC-derived endothelial cells reveal aberrant p38 MAPK signaling in atypical hemolytic uremic syndrome. Stem Cell Reports 2021:S2213-6711(21)00377-5. [PMID: 34388364 DOI: 10.1016/j.stemcr.2021.07.011] [Reference Citation Analysis]
31 Noris M, Remuzzi G. Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology 2017;37:447-63. [DOI: 10.1016/j.semnephrol.2017.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
32 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23. [PMID: 28215731 DOI: 10.1016/j.blre.2017.02.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
34 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
35 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
36 Miyata T, Uchida Y, Yoshida Y, Kato H, Matsumoto M, Kokame K, Fujimura Y, Nangaku M. No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome. Int J Hematol 2016;104:223-7. [PMID: 27194432 DOI: 10.1007/s12185-016-2021-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2015;11:245-52. [PMID: 25599621 DOI: 10.1038/nrneph.2014.250] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
38 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
39 Liu D, Ding Q, Dai DF, Padhy B, Nayak MK, Li C, Purvis M, Jin H, Shu C, Chauhan AK, Huang CL, Attanasio M. Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling. JCI Insight 2021;6:146959. [PMID: 33986189 DOI: 10.1172/jci.insight.146959] [Reference Citation Analysis]
40 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Roumenina LT, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: source, barrier, and target of defensive mediators. Immunol Rev 2016;274:307-29. [PMID: 27782324 DOI: 10.1111/imr.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
42 Zhu J, Chaki M, Lu D, Ren C, Wang SS, Rauhauser A, Li B, Zimmerman S, Jun B, Du Y, Vadnagara K, Wang H, Elhadi S, Quigg RJ, Topham MK, Mohan C, Ozaltin F, Zhou XJ, Marciano DK, Bazan NG, Attanasio M. Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production. Am J Physiol Renal Physiol 2016;310:F895-908. [PMID: 26887830 DOI: 10.1152/ajprenal.00431.2015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
43 Bowen EE, Coward RJ. Advances in our understanding of the pathogenesis of hemolytic uremic syndromes. Am J Physiol Renal Physiol. 2018;314:F454-F461. [PMID: 29167171 DOI: 10.1152/ajprenal.00376.2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
44 Fakhouri F, Loirat C. Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Seminars in Hematology 2018;55:150-8. [DOI: 10.1053/j.seminhematol.2018.04.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
45 Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2019;66:235-46. [DOI: 10.1016/j.pcl.2018.09.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
46 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
47 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
48 Bezdíčka M, Pavlíček P, Bláhová K, Háček J, Zieg J. Various phenotypes of disease associated with mutated DGKE gene. Eur J Med Genet 2020;63:103953. [PMID: 32413569 DOI: 10.1016/j.ejmg.2020.103953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
50 Fu W, Li M, Lin H, Xu Y, Han W, Chen H, Sun L. Cyclosporine A relieved proteinuria and hypoproteinemia in DGKE nephropathy. Clin Chim Acta 2021;518:78-82. [PMID: 33741360 DOI: 10.1016/j.cca.2021.02.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Jennings W, Doshi S, D'Souza K, Epand RM. Molecular properties of diacylglycerol kinase-epsilon in relation to function. Chem Phys Lipids 2015;192:100-8. [PMID: 26134136 DOI: 10.1016/j.chemphyslip.2015.06.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
52 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 124] [Cited by in F6Publishing: 101] [Article Influence: 24.8] [Reference Citation Analysis]
53 So V, Jalan D, Lemaire M, Topham MK, Hatch GM, Epand RM. Diacylglycerol kinase epsilon suppresses expression of p53 and glycerol kinase in mouse embryo fibroblasts. Biochim Biophys Acta 2016;1861:1993-9. [PMID: 27713003 DOI: 10.1016/j.bbalip.2016.09.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
54 Moroi AJ, Zwifelhofer NM, Riese MJ, Newman DK, Newman PJ. Diacylglycerol kinase ζ is a negative regulator of GPVI-mediated platelet activation. Blood Adv 2019;3:1154-66. [PMID: 30967391 DOI: 10.1182/bloodadvances.2018026328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
55 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
56 Hyvärinen S, Jokiranta TS. Minor Role of Plasminogen in Complement Activation on Cell Surfaces. PLoS One 2015;10:e0143707. [PMID: 26637181 DOI: 10.1371/journal.pone.0143707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]